No Data
No Data
Rapport Therapeutics Reports Positive Early Data for Epilepsy Drug Candidate
Express News | Rapport Therapeutics' Positron Emission Tomography Trial And Second Multiple Ascending Dose Trial For RAP-219, Demonstrated RAP-219 Achieved Target Receptor Occupancy Associated With Maximal Efficacy In Prior Preclinical Models Within Five Days Of...
Express News | Rapport Therapeutics Inc - Phase 2a Trial of Rap-219 on Track, Data Expected Mid-2025
Express News | Rapport Therapeutics Inc - Rap-219 Well Tolerated in Mad-2 Trial
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
Express News | Rapport Therapeutics Announces New Phase 1 Data, Further Supporting Rap-219's Transformative Potential for CNS Disorders